Elixir Capital

how big is Elixir Capital?

As of Jun 06, Elixir Capital Ltd has a market capitalization of 69.55 Cr, with recent net sales of 35.36 Cr and net profit of 9.32 Cr over the last four quarters. Shareholder's funds are 48.43 Cr, and total assets amount to 96.38 Cr as of Mar'24.

Market Cap: As of Jun 06, Elixir Capital Ltd has a market capitalization of 69.55 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 35.36 Cr. The sum of Net Profit for the same period is 9.32 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending Mar'24. The Shareholder's Funds are reported at 48.43 Cr, while Total Assets amount to 96.38 Cr.

Who are in the management team of Elixir Capital?

As of March 2023, the management team of Elixir Capital includes Dipan Mehta (Chairman & Non Executive Director), Radhika Mehta (Executive Director), Dilip Kapadia (Independent Non Executive Director), and Suril V Shah (Independent Non Executive Director). Each member contributes to the company's governance and strategic direction.

As of March 2023, the management team of Elixir Capital includes the following individuals:<BR><BR>1. Dipan Mehta - Chairman & Non Executive Director<BR>2. Radhika Mehta - Executive Director / Whole Time Director<BR>3. Dilip Kapadia - Independent Non Executive Director<BR>4. Suril V Shah - Independent Non Executive Director<BR><BR>Each of these members plays a significant role in the governance and strategic direction of the company.

What does Elixir Capital do?

Elixir Capital Ltd is a micro cap financial services holding company in the NBFC sector, incorporated in 1994, with recent net sales of -4 Cr and a net profit of -6 Cr as of March 2025. Key metrics include a market cap of Rs 68 Cr, a P/E ratio of 7.00, and a dividend yield of 1.00%.

Overview: <BR>Elixir Capital Ltd is a financial services holding company operating in the Non Banking Financial Company (NBFC) sector, categorized as a micro cap.<BR><BR>History: <BR>Elixir Capital Ltd was incorporated in 1994 and was formerly known as Axis Capital Markets (India) Ltd. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: -4 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -6 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 68 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 7.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 1.00% <BR>Debt-Equity: 0.55 <BR>Return on Equity: 16.98% <BR>Price to Book: 1.23 <BR><BR>Contact Details: <BR>Address: 58 Mittal Chambers, 228 Nariman Point Mumbai Maharashtra : 400021 <BR>Tel: 91-22-61151919 <BR>Email: dipanmehta@vsnl.com <BR>Website: http://www.elixircapital.in

Has Elixir Capital declared dividend?

Elixir Capital Ltd has declared a 12% dividend, amounting to 1.2 per share, with an ex-date of August 16, 2024. While the dividend yield is 1%, recent total returns show significant fluctuations, particularly a -58.84% return over the last 6 months, but positive returns over longer periods.

Elixir Capital Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 16 Aug 2024<BR><BR>Dividend Yield: 1%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -58.84%, the dividend return was 0%, resulting in a total return of -58.84%.<BR><BR>Over the past year, the price return was 6.11%, the dividend return was 0.96%, leading to a total return of 7.07%.<BR><BR>In the 2-year period, the price return was 182.2%, with a dividend return of 5.35%, culminating in a total return of 187.55%.<BR><BR>For the 3-year period, the price return was 155.54%, the dividend return was 7.13%, resulting in a total return of 162.67%.<BR><BR>In the 4-year period, the price return was 252.5%, the dividend return was 10.20%, leading to a total return of 262.7%.<BR><BR>Over the last 5 years, the price return was 327.27%, with a dividend return of 19.67%, resulting in a total return of 346.94%.<BR><BR>Overall, while Elixir Capital Ltd has declared a dividend, the recent total returns indicate significant fluctuations, particularly in the short term, with notable positive returns over longer periods. The dividend yield is relatively low, suggesting that while there is a return from dividends, the focus may be more on price appreciation in the stock.

Who are the peers of the Elixir Capital?

Elixir Capital's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Arnold Holdings, Ladderup Finance, Biogen Pharma, and BAMPSL Sec. In terms of management risk, growth, and capital structure, Elixir Capital shows average performance compared to its peers, with a 1-year return of -0.17%.

Peers: The peers of Elixir Capital are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Arnold Holdings, Ladderup Finance, Biogen Pharma, and BAMPSL Sec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, Muthoot Finance, while Average management risk is found at Jio Financial and Elixir Capital. Good management risk is noted at Shriram Finance, and Below Average management risk is present at Arnold Holdings, Ladderup Finance, Biogen Pharma, and BAMPSL Sec. Growth is Excellent for Jio Financial, Elixir Capital, and Arnold Holdings, while Good growth is seen at Bajaj Finance, Cholaman.Inv.&Fn, and Shriram Finance. Average growth is noted at Muthoot Finance, and Below Average growth is present at Ladderup Finance and Biogen Pharma. Capital Structure is Excellent for Bajaj Finance, Jio Financial, Shriram Finance, Muthoot Finance, Arnold Holdings, Elixir Capital, and BAMPSL Sec., while Good capital structure is seen at Cholaman.Inv.&Fn, and Below Average at Ladderup Finance and Biogen Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ladderup Finance at 72.80%, while the lowest is Arnold Holdings at -47.96%. Elixir Capital's 1-year return is -0.17%, which is higher than Arnold Holdings but lower than most peers. Additionally, the six-month return is negative for Elixir Capital, Arnold Holdings, and Biogen Pharma.

What is the technical trend for Elixir Capital?

As of May 16, 2025, Elixir Capital's technical trend has shifted to a moderate bearish stance, supported by bearish MACD and moving averages, while Bollinger Bands indicate mild bearishness, despite mixed signals from the KST.

As of 16 May 2025, the technical trend for Elixir Capital has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD indicates a bearish trend, while the daily moving averages also confirm a bearish outlook. The Bollinger Bands on both weekly and monthly time frames are mildly bearish, further supporting the negative sentiment. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating mixed signals in the longer term. Overall, the indicators suggest a prevailing bearish trend for Elixir Capital.

Who are the top shareholders of the Elixir Capital?

The top shareholder of Elixir Capital is Dipan Anil Mehta, holding 36.6%. Other significant shareholders include Shamyak Investment Private Limited with 6.47% and individual investors collectively owning 17.72%.

The top shareholders of Elixir Capital include the promoters, with Dipan Anil Mehta holding the largest share at 36.6%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Shamyak Investment Private Limited, which owns 6.47%. Additionally, individual investors collectively hold 17.72% of the shares.

When is the next results date for Elixir Capital?

The next results date for Elixir Capital is 14 November 2025.

The next results date for Elixir Capital is scheduled for 14 November 2025.

How has been the historical performance of Elixir Capital?

Elixir Capital has experienced significant growth in net sales and total operating income, rising from 3.76 Cr in Mar'23 to 35.37 Cr in Mar'25, despite declines in profitability metrics and increased expenditures. The company shows a recovery phase with improved cash flow and asset growth, although profit after tax decreased from 20.96 Cr in Mar'24 to 12.64 Cr in Mar'25.

Answer:<BR>The historical performance of Elixir Capital shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Elixir Capital's net sales have shown a notable increase from 3.76 Cr in Mar'23 to 35.37 Cr in Mar'25, indicating a strong recovery and growth trajectory. Total operating income followed a similar trend, rising from 3.76 Cr in Mar'23 to 35.37 Cr in Mar'25. However, total expenditure also increased, from 5.70 Cr in Mar'23 to 15.33 Cr in Mar'25, reflecting higher employee costs and other expenses. Operating profit (PBDIT) saw a peak of 27.43 Cr in Mar'24 but dropped to 20.87 Cr in Mar'25, while profit before tax decreased from 26.08 Cr in Mar'24 to 18.02 Cr in Mar'25. The profit after tax also declined from 20.96 Cr in Mar'24 to 12.64 Cr in Mar'25, resulting in a decrease in the PAT margin from 65.44% to 36.31%. On the balance sheet, total assets increased from 96.38 Cr in Mar'24 to 115.58 Cr in Mar'25, with total liabilities also rising from 96.38 Cr to 115.58 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities turned positive at 2.00 Cr in Mar'25 after a negative trend in the previous year, while closing cash and cash equivalents increased to 10.00 Cr in Mar'25 from 9.00 Cr in Mar'24. Overall, Elixir Capital's financial performance reflects a recovery phase with growth in sales and assets, despite some declines in profitability metrics in the most recent year.

Is Elixir Capital overvalued or undervalued?

As of November 17, 2025, Elixir Capital is considered overvalued with a PE ratio of -90.87 and an EV to EBITDA of 60.62, significantly underperforming its peers and the market, evidenced by a year-to-date return of -70.74%.

As of 17 November 2025, Elixir Capital's valuation grade has moved from attractive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its PE ratio of -90.87, an EV to EBITDA ratio of 60.62, and a Price to Book Value of 0.95. These ratios suggest that the company's earnings and operational performance are not aligned with its market price, raising concerns about its valuation.<BR><BR>When compared to peers, Elixir Capital's metrics stand out unfavorably. For instance, Bajaj Finance has a PE ratio of 34.85 and an EV to EBITDA of 19.61, while Life Insurance boasts a PE ratio of 11.33 and an EV to EBITDA of 9.36, both of which highlight the relative overvaluation of Elixir Capital. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -70.74%, significantly underperforming the Sensex's 8.72% return, further reinforcing the notion that Elixir Capital is currently overvalued.

Are Elixir Capital Ltd latest results good or bad?

Elixir Capital Ltd's latest results are poor, with a 40.25% decline in revenue and a 79.55% drop in net profit year-on-year, alongside significantly reduced operating profit margins. The company's stock has also fallen sharply, indicating challenges in its business model and sustainability.

Elixir Capital Ltd's latest results indicate a challenging financial situation. In Q2 FY26, the company reported revenue of ₹11.09 crores, which is a significant decline of 40.25% year-on-year. Additionally, the consolidated net profit fell sharply by 79.55% compared to the same quarter last year, landing at ₹1.71 crores. This decline in profitability is compounded by a substantial compression in operating profit margins, which dropped from 85.26% in Q2 FY25 to 41.16% in the latest quarter.<BR><BR>The stock has also faced considerable volatility, trading at ₹98.50, reflecting a year-to-date decline of 70.79% and a 49.33% drop over the past twelve months. This performance starkly contrasts with the broader NBFC sector, which has shown resilience, making Elixir Capital's underperformance particularly concerning.<BR><BR>Overall, the results can be characterized as bad, with significant declines in both revenue and profit, alongside deteriorating margins and a lack of institutional support. The company's business model appears vulnerable to market fluctuations, raising questions about its sustainability in the current economic environment.

Should I buy, sell or hold Elixir Capital Ltd?

Why is Elixir Capital Ltd falling/rising?

As of 16-Mar, Elixir Capital Ltd's stock price is at Rs. 90.40, down 2.9%, and has reached a 52-week low of Rs. 86, indicating a bearish trend with significant selling pressure and decreased investor participation. The stock has underperformed its sector and shows high volatility, trading below its moving averages.

As of 16-Mar, Elixir Capital Ltd's stock price is falling, currently at Rs. 90.40, which reflects a decrease of Rs. 2.7 or 2.9%. The stock has been on a downward trend, having lost 5.78% over the last three days. Today, it reached a new 52-week low of Rs. 86, indicating significant selling pressure. The stock's performance has underperformed its sector by 3.69% today, and it has also shown a substantial decline of 17.56% over the past month, compared to a 9.34% drop in the benchmark Sensex.<BR><BR>Additionally, Elixir Capital is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. The stock has exhibited high volatility today, with an intraday volatility of 5.23%, and it has traded in a wide range of Rs. 9.5, further indicating instability. Investor participation has also decreased significantly, with delivery volume falling by 82.54% against the 5-day average, which may reflect a lack of confidence among investors. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Elixir Capital?